Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187133 | 0.84 | KCNJ1 (0.51) | HCAR2KCNJ1GAAALDH1A1KDM4E | |
| SCHEMBL10187132 | 0.69 | HCAR2 (0.49) | HCAR2GAAALDH1A1 | |
| SCHEMBL10312752 | 0.66 | KCNJ1 (0.51) | KCNJ1ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL10312549 | 0.63 | HDAC1 (0.40) | ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL8564072 | 0.59 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPT | |
| SCHEMBL7038561 | 0.59 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPT | |
| SCHEMBL15453274 | 0.57 | — | — | |
| SCHEMBL16906442 | 0.54 | KCNJ1 (1.00) | KCNJ1ALDH1A1MAPTTDP1 | |
| SCHEMBL1553946 | 0.54 | — | — | |
| SCHEMBL6854100 | 0.53 | NPC1 (0.65) | GAAALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | HCAR2 2/4885KCNJ1 1461/4885GAA 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.